Market Performance - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling by 2.23% to 26,775.57 points, and the Hang Seng Tech Index dropping by 3.36% to 5,526.31 points [1] - Major technology stocks saw significant losses, including Alibaba down 3.49%, Tencent down 1.24%, and JD.com down 1.69% [1] - Gold and silver prices fell sharply, with Shandong Gold and Chifeng Gold both dropping over 12% [1] Company Earnings Forecasts - Haiprime (09989.HK) expects a net profit of 284 million to 377 million yuan for 2025, a decrease of 41.71% to 56.09% year-on-year [2] - Datang Power (00991.HK) anticipates a net profit of approximately 6.8 billion to 7.8 billion yuan for 2025, an increase of about 51% to 73% year-on-year [6] - Longhua Automobile (02333.HK) projects total revenue of 222.79 billion yuan for 2025, a year-on-year growth of 10.19% [4] - CICC (03908.HK) forecasts a net profit of 8.542 billion to 10.535 billion yuan for 2025, an increase of 50% to 85% year-on-year [5] Company Warnings - Kaisa New Energy (01108.HK) issued a profit warning, expecting a net loss increase of approximately 90.07 million to 290 million yuan for 2025 [7] - Xinyi Alloy (00505.HK) also issued a profit warning, anticipating a 50% decrease in profit attributable to equity shareholders for 2025 [8] - Fudan Zhangjiang (01349.HK) expects a net loss of approximately 120 million to 180 million yuan for 2025 [9] Strategic Developments - Innovation Intelligence (02121.HK) signed a strategic cooperation agreement with Shanghai Jiao Tong University Hainan Research Institute [11] - Zhonghui Biotech-B (02627.HK) received approval from the National Medical Products Administration for its trivalent influenza virus subunit vaccine [12]

公告称，2025年度公司核心产品泰它西普、维迪西妥单抗国内销售收入实现快速增长，成为业绩核心增 长引擎；同时，公司成功达成重磅合作，授予Vor Biopharma Inc泰它西普除大中华区以外全球范围内的 独家开发与商业化权利，技术授权收入大幅增加，部分海外研发投入由授权方承担。此外，公司通过优 化管理、迭代生产工艺等举措，降低了产品单位生产成本，提升了产品毛利率，另外，销售费用率明显 下降。综合多方面积极因素，公司盈利效率大幅改善，预计2025年度净利润将实现扭亏为盈。 消息面上，1月30日，荣昌生物发布公告，经公司财务部门初步测算，预计2025年度营业收入约人民币 32.5亿元，与上年同期相比，将增加收入约人民币15.33亿元，同比增加约89%。公司预计2025年度实现 归属于母公司所有者的净利润约人民币7.16亿元，与上年同期相比，实现扭亏为盈。公司预计2025年度 归属于母公司所有者扣除非经常性损益后的净利润约人民币7850万元，与上年同期相比，实现扭亏为 盈。 荣昌生物(09995)盈喜后涨近4%，截至发稿，涨3.68%，报87.3港元，成交606.74万港元。 ...

盘面上，大型科技股普跌，阿里巴巴跌3.25%，腾讯控股跌1.32%，京东集团跌1.6%，小米集团跌 2.99%，网易跌3.41%，美团跌2.67%，快手跌3.49%，哔哩哔哩跌4.47%；黄金股继续下跌，山东黄金跌 超10%；汽车股走弱，小鹏汽车跌9%；芯片股跌幅居前，华虹半导体（核心股）跌超10%；澳门1月博 彩收入胜预期，濠赌股逆势上涨。 企业资讯 海普瑞(09989.HK)：预计2025年净利润2.84亿元-3.77亿元，同比下降41.71%-56.09%。 大唐发电(00991.HK)：2025年累计完成上网电量约2731.092亿千瓦时，同比上升约1.41%。 长城汽车(02333.HK)：2025年营业总收入2227.9亿元，同比增长10.19%；净利润99.12亿元，同比减少 21.71%。 中金公司(03908.HK)：预计2025年净利润85.42亿元到105.35亿元，同比增加50%到85%。 2月2日，港股早盘低开低走全线下挫，截止午盘，恒生指数跌2.4%报26730.78点，恒生科技指数跌 3.68%报5507.77点，国企指数跌2.71%报9064.43点，红筹指数跌2.75%报42 ...

Core Insights - The strategic collaboration and licensing agreement between CSPC Pharmaceutical Group and AstraZeneca for the development of innovative long-acting peptide drugs has a potential transaction value of up to $18.5 billion, setting a new record for BD transactions among Chinese pharmaceutical companies [2][13]. Group 1: Transaction Details - The agreement includes an upfront payment of $1.2 billion and up to $17.3 billion in milestone payments [2][13]. - This transaction is part of a broader trend where multiple innovative drug BD transactions have been completed since the beginning of 2026, indicating a positive trend for Chinese innovative drugs going global [13][20]. Group 2: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) has shown strong performance, leading its peers since 2025, with a return of 75.03% [4][17]. - The index is characterized by high purity, elasticity, and sharpness, demonstrating strong aggressiveness in the rebound of the innovative drug market [4][17]. Group 3: Historical Context - In 2025, the total value of innovative drug BD outbound licensing transactions from China reached $135.655 billion, with a total of 157 transactions, both setting historical highs [20][21]. - The historical annual returns for the Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index from 2021 to 2025 were -22.72%, -16.48%, -19.76%, -14.16%, and 66.32% respectively [6][18].

Summary of Conference Call Records Company Overview - **Company**: 荣昌生物 (Rongchang Biopharma) - **Industry**: Biopharmaceuticals Key Points Financial Performance - **2025 Revenue Forecast**: Expected to reach 3.25 billion (32.5亿), representing an 89% year-over-year increase [1] - **Net Profit**: Anticipated net profit of 716 million (7.16亿) and adjusted net profit of 785 million (7.85亿), marking a turnaround to profitability [1][2] Business Development (BD) and Product Pipeline - **Domestic Sales Growth**: Significant increase in domestic product sales, with expectations of over 2.3 billion (23亿) from two major products by 2025 [2] - **BD Transactions**: Multiple BD transactions expected in 2025, including a $45 million upfront payment and $80 million in warrants from the licensing of 泰它西普 (Taitasip) to VOR [2] - **RC148 Licensing**: RC148 licensed to AbbVie for $650 million upfront and a total potential of $5.6 billion, with promising early clinical results [3] Clinical Development - **RC148 Clinical Trials**: Potential for direct initiation of Phase III clinical trials in overseas markets, targeting 1L NSCLC and 1L CRC as initial indications [3] - **泰它西普 (Taitasip)**: Ongoing global Phase III clinical trials, with FDA fast track designation for pSS and expected initiation of global trials by VorBio [4] - **维迪西妥单抗 (Vidisicimab)**: Completion of Phase II clinical trials for 2L UC and acceleration of Phase III trials for 1L UC, with a BLA submission expected from Pfizer in 1H26 [4] Market Position and Future Outlook - **Market Dynamics**: Controlled reduction in core product reimbursement rates, with rapid revenue growth anticipated [1] - **Strategic Partnerships**: Collaboration with AbbVie expected to enhance ADC + IO strategy, with potential for RC148 to become a cornerstone in first-line cancer treatment [3] Additional Insights - **Regulatory Approvals**: Anticipation of multiple milestones in 2026, including potential approvals for various indications [4] - **Long-term Growth**: Continued expansion of domestic business and BD income expected to drive significant revenue growth in 2026 [2]

每经AI快讯，荣昌生物(09995.HK)盈喜后涨近4%，截至发稿涨3.68%，报87.3港元，成交606.74万港 元。 ...

消息面上，1月30日，荣昌生物发布公告，经公司财务部门初步测算，预计2025年度营业收入约人民币 32.5亿元，与上年同期相比，将增加收入约人民币15.33亿元，同比增加约89%。公司预计2025年度实现 归属于母公司所有者的净利润约人民币7.16亿元，与上年同期相比，实现扭亏为盈。公司预计2025年度 归属于母公司所有者扣除非经常性损益后的净利润约人民币7850万元，与上年同期相比，实现扭亏为 盈。 公告称，2025年度公司核心产品泰它西普、维迪西妥单抗国内销售收入实现快速增长，成为业绩核心增 长引擎；同时，公司成功达成重磅合作，授予Vor Biopharma Inc泰它西普除大中华区以外全球范围内的 独家开发与商业化权利，技术授权收入大幅增加，部分海外研发投入由授权方承担。此外，公司通过优 化管理、迭代生产工艺等举措，降低了产品单位生产成本，提升了产品毛利率，另外，销售费用率明显 下降。综合多方面积极因素，公司盈利效率大幅改善，预计2025年度净利润将实现扭亏为盈。 智通财经APP获悉，荣昌生物(09995)盈喜后涨近4%，截至发稿，涨3.68%，报87.3港元，成交606.74万 港元。 ...

Investment Rating - The report maintains an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, while China National Pharmaceutical Group is rated "Neutral" [1]. Core Insights - The Hong Kong healthcare sector experienced a broad-based correction due to capital pressures, with pharmaceutical distribution remaining relatively stable [4][28]. - The Hang Seng Healthcare Index fell by 3.0% this week, underperforming the Hang Seng Index by 5.4 percentage points, but has gained 8.6% year-to-date, outperforming the Hang Seng Index by 1.7 percentage points [14][27]. - The top five gainers in the sector included Leads Biolabs-B (+19.3%), Sihuan Pharmaceutical (+17.9%), and Tigermed (+7.6%), while the bottom five decliners included Medlive Technology (-16.2%) and Laekna-B (-14.1%) [4][29]. Summary by Sections Market Performance - The report indicates that various sub-sectors within the healthcare market have experienced declines, with pharmaceutical distribution down by 0.3%, internet healthcare down by 2.1%, and medical devices down by 5.0% [4][28]. Company Updates - Rongchang Biopharmaceutical announced a revenue forecast of 3.25 billion yuan for 2025, representing a year-on-year increase of 89%, and has turned a profit [11]. - A collaboration agreement was signed between CSPC Pharmaceutical and AstraZeneca, involving a total payment of $18.5 billion for the licensing of GLP-1 long-acting assets [11]. - AstraZeneca plans to invest $15 billion in China by 2030, focusing on expanding drug manufacturing and R&D capabilities [12]. - Kangzheng Pharmaceutical's lebrikizumab cream has been approved for the treatment of non-segmental vitiligo in patients aged 12 and older [12]. Regulatory Developments - The National Health Commission approved a pilot program for internet-based first consultations in Beijing, which is expected to accelerate prescription outflow [13].

2、国家统计局、中国物流与采购联合会31日发布2026年1月份中国采购经理指数。数据显示，2026年1 月份中国制造业采购经理指数为49.3%，比上月下降0.8个百分点。 3、香港特区政府财政司司长陈茂波2月1日表示，海外企业和投资者对投资香港的信心正在加强。去年 海内外企业的驻港公司以及香港的初创公司数目均大增逾一成，分别超过11000家和5200家。另据一些 外国商会最近所做的调查，其大部分会员企业对香港营商前景感到乐观，正面预期的比例亦创近年新 高。在第十九届亚洲金融论坛举行期间，陈茂波先后与来自欧美和中东的政商领袖，以及内地和国际多 边组织代表会面，他们都不约而同指香港的前景正面，并涌现更多新机遇。 4、受获利回吐和短期期货交易者多头平仓等因素影响，国际黄金和白银价格1月30日继续大幅下跌，均 创下数十年来最大单日跌幅。分析人士认为，经历近一个月来金银价格暴涨，此次市场抛售在所难免。 此外芝加哥商品交易所于当地时间上周五宣布上调Comex黄金和白银期货的交易保证金要求。根据声 明，对于非高风险账户，黄金期货的保证金将从当前合约价值的6%提高至8%，高风险账户的保证金则 从6.6%上调至8.8%。白银方 ...

Investment Rating - The report maintains an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, while China National Pharmaceutical Group is rated "Neutral" [1]. Core Insights - The Hong Kong healthcare sector experienced a broad-based correction due to capital pressures, with pharmaceutical distribution remaining relatively stable [4][28]. - The Hang Seng Healthcare Index fell by 3.0% this week, underperforming the Hang Seng Index by 5.4 percentage points, but has gained 8.6% year-to-date, outperforming the Hang Seng Index by 1.7 percentage points [14][27]. - The top five gainers in the sector included Leads Biolabs-B (+19.3%), Sihuan Pharmaceutical (+17.9%), and Tigermed (+7.6%), while the bottom five decliners included Medlive Technology (-16.2%) and Laekna-B (-14.1%) [4][29]. Summary by Sections Market Performance - The report indicates that various sub-sectors within the Hong Kong healthcare market experienced declines, with pharmaceutical distribution down by 0.3%, internet healthcare down by 2.1%, and medical devices down by 5.0% [4][28]. Company Highlights - Rongchang Biopharmaceutical announced a revenue forecast of 3.25 billion yuan for 2025, representing an 89% year-on-year increase, and reported a turnaround to profitability [11]. - A collaboration agreement was signed between CSPC Pharmaceutical and AstraZeneca, involving a total payment of $18.5 billion for the licensing of GLP-1 long-acting assets [11]. - AstraZeneca plans to invest $15 billion in China by 2030, focusing on expanding drug manufacturing and R&D capabilities [12]. - Kangzheng Pharmaceutical's lebrikizumab cream has been approved for the treatment of non-segmental vitiligo in patients aged 12 and older [12]. Regulatory Developments - The National Health Commission approved a pilot program for internet-based first consultations in Beijing, which is expected to accelerate prescription outflow and improve access to healthcare services [13].